Literature DB >> 34338931

Unveiling the relationship between autonomic involvement, fatigue, and cognitive dysfunction in early relapsing-remitting multiple sclerosis.

Alessandro Dinoto1, Sara Baldini2, Maria Elisa Morelli2, Fulvio Pasquin2, Alessio Bratina2, Antonio Bosco2, Arianna Sartori2, Paolo Manganotti2.   

Abstract

BACKGROUND: Fatigue is a common, yet disabling, symptom in patients with multiple sclerosis (PwMS). Fatigue has shown to be associated with self-reported autonomic nervous system (ANS) symptoms, particularly for cognitive fatigue; however, the question whether ANS involvement is related to cognitive impairment has never been addressed. We performed a study to unveil the complex relationship between fatigue, ANS symptoms, and cognitive impairment.
METHODS: We prospectively recruited early PwMS that were tested with Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS), State-Trait Anxiety Inventory (STAI), Beck Depression Inventory (BDI), Modified Fatigue Impact Scale (MFIS) and Composite Autonomic Symptoms Scale-31 (COMPASS-31) scale. We performed a comparison between fatigued and non-fatigued patients and between cognitive unimpaired and impaired patients. We evaluated the association of COMPASS-31, MFIS, BDI, STAI, and BICAMS scores, and the analysis was repeated for each scale's sub-scores. A multivariable analysis was performed to elucidate predictors of fatigue.
RESULTS: Forty-four patients were recruited. Fatigued patients had higher COMPASS-31 total, orthostatic intolerance, secretomotor, and pupillomotor scores. No differences in fatigue and ANS symptoms were found between cognitive impaired and unimpaired patients. MFIS total score correlated with STAI state (p = 0.002) and trait (p < 0.001), BDI (p < 0.001), COMPASS-31 total (p < 0.001), orthostatic intolerance (p < 0.001), pupillomotor scores (p = 0.006). Multivariable analysis showed that BDI (p < 0.001) and COMPASS-31 (p = 0.021) predicted MFIS score. Sub-scores analysis showed that orthostatic intolerance has a relevant role in fatigue.
CONCLUSION: ANS symptoms are closely related with fatigue. Orthostatic intolerance may have a predominant role. Cognitive impairment seems not to be associated with ANS symptoms.
© 2021. Fondazione Società Italiana di Neurologia.

Entities:  

Keywords:  Autonomic nervous system; Cognitive impairment; Fatigue; Multiple sclerosis

Year:  2021        PMID: 34338931     DOI: 10.1007/s10072-021-05487-6

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  26 in total

1.  Progressive multiple sclerosis patients have a higher burden of autonomic dysfunction compared to relapsing remitting phenotype.

Authors:  Ivan Adamec; Luka Crnošija; Anamari Junaković; Magdalena Krbot Skorić; Mario Habek
Journal:  Clin Neurophysiol       Date:  2018-06-04       Impact factor: 3.708

Review 2.  Cardiovascular autonomic dysfunction in multiple sclerosis: a meta-analysis.

Authors:  Juan Manuel Racosta; Luciano A Sposato; Sarah A Morrow; Lauren Cipriano; Kurt Kimpinski; Kurt Kimpiski; Marcelo Kremenchutzky
Journal:  Mult Scler Relat Disord       Date:  2015-02-23       Impact factor: 4.339

3.  Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability.

Authors:  P Flachenecker; K Reiners; M Krauser; A Wolf; K V Toyka
Journal:  Mult Scler       Date:  2001-10       Impact factor: 6.312

4.  [Evaluation of reinductions in a modern protocol for the treatment of childhood acute lymphoblastic leukaemias. Analysis of the D-74 protocol (author's transl)].

Authors:  J J Ortega; G Javier
Journal:  Sangre (Barc)       Date:  1981

5.  Autonomic symptom burden can predict disease activity in early multiple sclerosis.

Authors:  Magdalena Krbot Skorić; Luka Crnošija; Tereza Gabelić; Barbara Barun; Ivan Adamec; Anamari Junaković; Tin Pavičić; Berislav Ruška; Mario Habek
Journal:  Mult Scler Relat Disord       Date:  2019-01-03       Impact factor: 4.339

6.  Autonomic dysfunction in clinically isolated syndrome suggestive of multiple sclerosis.

Authors:  Luka Crnošija; Ivan Adamec; Mila Lovrić; Anamari Junaković; Magdalena Krbot Skorić; Ivo Lušić; Mario Habek
Journal:  Clin Neurophysiol       Date:  2015-06-16       Impact factor: 3.708

Review 7.  Pathophysiology, assessment and management of multiple sclerosis fatigue: an update.

Authors:  Mariarosa Rottoli; Sara La Gioia; Barbara Frigeni; Valeria Barcella
Journal:  Expert Rev Neurother       Date:  2016-10-21       Impact factor: 4.618

8.  Sympathetic cardiovascular and sudomotor functions are frequently affected in early multiple sclerosis.

Authors:  Mario Habek; Luka Crnošija; Mila Lovrić; Anamari Junaković; Magdalena Krbot Skorić; Ivan Adamec
Journal:  Clin Auton Res       Date:  2016-07-22       Impact factor: 4.435

9.  Hypotension unawareness in profound orthostatic hypotension.

Authors:  Steven D Arbogast; Amer Alshekhlee; Zulfiqar Hussain; Kevin McNeeley; Thomas C Chelimsky
Journal:  Am J Med       Date:  2009-06       Impact factor: 4.965

10.  Autonomic dysfunction in multiple sclerosis is better detected by heart rate variability and is not correlated with central autonomic network damage.

Authors:  Gonçalo Videira; Pedro Castro; Bítia Vieira; João Pedro Filipe; Rosa Santos; Elsa Azevedo; Maria José Sá; Pedro Abreu
Journal:  J Neurol Sci       Date:  2016-05-25       Impact factor: 3.181

View more
  2 in total

Review 1.  Heart rate variability and fatigue in MS: two parallel pathways representing disseminated inflammatory processes?

Authors:  Guadalupe Garis; Michael Haupts; Thomas Duning; Helmut Hildebrandt
Journal:  Neurol Sci       Date:  2022-09-20       Impact factor: 3.830

Review 2.  Brain Structural and Functional Alterations in Multiple Sclerosis-Related Fatigue: A Systematic Review.

Authors:  Chiara Barbi; Francesca Benedetta Pizzini; Stefano Tamburin; Alice Martini; Anna Pedrinolla; Fabio Giuseppe Laginestra; Gaia Giuriato; Camilla Martignon; Federico Schena; Massimo Venturelli
Journal:  Neurol Int       Date:  2022-06-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.